As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...